187 related articles for article (PubMed ID: 23663694)
1. Serum biomarkers of papillary thyroid cancer.
Makki FM; Taylor SM; Shahnavaz A; Leslie A; Gallant J; Douglas S; Teh E; Trites J; Bullock M; Inglis K; Pinto DM; Hart RD
J Otolaryngol Head Neck Surg; 2013 Feb; 42(1):16. PubMed ID: 23663694
[TBL] [Abstract][Full Text] [Related]
2. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
3. Increased gene expression of TIMP1 and CHI3L1 in fine-needle aspiration biopsy samples from papillary thyroid cancer as compared to benign nodules.
Dimitrova I; Shinkov A; Dodova R; Ivanova R; Kirilov G; Kyurkchiyan S; Kaneva R; Kovatcheva R
Diagn Cytopathol; 2021 Sep; 49(9):1045-1051. PubMed ID: 34170085
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
5. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.
Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403
[TBL] [Abstract][Full Text] [Related]
6. Hashimoto's thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value?
Divani SN; Kalodimos GP; Lioupis MA; Syrmos NC
Hell J Nucl Med; 2016; 19(3):250-253. PubMed ID: 27824965
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
8. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.
Hou X; Jiang L; Chen C; Zhu X; Ge M
Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079
[TBL] [Abstract][Full Text] [Related]
9. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination.
Ma H; Xu S; Yan J; Zhang C; Qin S; Wang X; Li N
Pol J Pathol; 2014 Oct; 65(3):202-9. PubMed ID: 25372417
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of Serum Cytokeratin 18, Carcinoembryonic Antigen, and Thyroglobulin in Patients with Papillary Thyroid Carcinoma.
Yan G; Zhou Y; Wu H; Xun H
Clin Lab; 2021 Feb; 67(2):. PubMed ID: 33616340
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
Prasad PA; Raju K
J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
15. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
Li M; Song Q; Li H; Lou Y; Wang L
PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
17. [Value of VEGF-C, VEGF-D and VEGFR-3 levels combined with serum TSH in diagnosis of papillary thyroid carcinoma].
Huang J; Li Y; Xue G; Zhang W; Li S; Zhang J; Wu J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Dec; 34(12):1814-7, 1821. PubMed ID: 25537909
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
19. BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.
Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Caleo A; Zeppa P; Esposito S; Fulciniti F; Vitale M
Endocrine; 2013 Aug; 44(1):165-71. PubMed ID: 23203004
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of expression of LGALS3BP gene in thyroid tissues and peripheral blood lymphocytes in patients with papillary thyroid cancer].
Kaliszewski K; Łukieńczuk T; Dobosz T; Rzeszutko M; Sadakierska-Chudy A
Endokrynol Pol; 2006; 57 Suppl A():38-44. PubMed ID: 17091455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
